In a late stage trial, Johnson & Johnson said its COVID vaccine candidate was 72 percent successful. In the United States, a third vaccine is closer to getting accepted. The Johnson & Johnson vaccine nominee will be reviewed Friday by an independent advisory committee to the FDA.
Johnson & Johnson said the shot was 72 percent successful in the U.S. in a late stage global trial and marginally less in countries where variations, such as South Africa, are more common. It will be the country’s first single-dose vaccine if approved by the FDA. It can be kept in a regular fridge as well.